Postpartum Depression Drugs Market To Reach $1.59 Billion By 2030

Postpartum Depression Drugs Market Growth & Trends

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland  Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July  2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

 Request a free sample copy or view report summary: Postpartum Depression Drugs Market Report

Postpartum Depression Drugs Market Report Highlights

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.

• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.

• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.

• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.

• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Postpartum Depression Drugs Market Segmentation

Grand View Research has segmented the postpartum depression drugs market based on type, treatment, route of administration, distribution channel, and region:

Postpartum Depression Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Postpartum Blues

• Postpartum Anxiety

• Postpartum Obsessive-Compulsive Disorder (OCD)

• Postpartum Post-Traumatic Stress Disorder (PTSD)

• Postpartum Panic Disorder

• Postpartum Psychosis

Postpartum Depression Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmacotherapy

• Hormonal Therapy

• Others

Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral

• Oral

• Others

Postpartum Depression Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others (online pharmacy)

Postpartum Depression Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players in the Postpartum Depression Drugs Market

• Sage Therapeutics, Inc.

• Pfizer Inc.

• Eli Lilly and Company

• GSK plc.

• Merck & Co., Inc.

• Biogen Inc. 

• Bausch Health Companies Inc.

• Cipla Inc.

• Novartis AG

• Teva Pharmaceutical Industries Ltd.